Progress and challenges of plant-derived nucleic acids as therapeutics in macrophage-mediated RNA therapy

Yu-Da Liu, Hao Chen, Yao Zhang, Yan Ge, Hao-Jie Yan, Qi Zhu, Li‐Hua PengFrontiers in Immunology 2023 · DOI

Abstract

Plant-derived nucleic acids, especially small RNAs, have demonstrated significant pharmacological potential in macrophage-mediated anti-tumor, immune-regulating, and antiviral therapies. This review explores the evidence for cross-kingdom regulation by plant-derived mRNAs and miRNAs, their therapeutic potential, and the delivery strategies using macrophages and natural exosome vehicles. It provides a foundation for plant-derived RNAs as a next generation of nucleic acid-based biotherapies.

Introduction: The Frontier of Cross-Kingdom Regulation

While traditionally viewed as simple dietary components, recent evidence suggests that plant nucleic acids (miRNAs, mRNAs, and tRNAs) can survive digestion, enter the mammalian bloodstream, and regulate host genes. This process, termed "cross-kingdom regulation," opens new avenues for therapy. However, developing these molecules as "biodrugs" faces challenges such as environmental instability and low bioavailability. This paper synthesizes research on how plant RNAs interact with the mammalian immune system—specifically macrophages—to evaluate their potential as clinical therapies.

Mechanisms of Action and Biogenesis

Plant-derived RNAs interfere with mammalian signaling pathways through functional mimicry. For example, certain plant miRNAs can bind to human TLR3 receptors or target the Wnt signaling pathway to inhibit cancers. The stability of these molecules is often attributed to their packaging in exosome-like nanovesicles, which protect them from the acidic stomach environment and blood RNases.

Overview of miRNA biogenesis and various extracellular secretion pathways.

Therapeutic Applications in Immune Modulation

The therapeutic successes of plant RNAs span anti-tumor, anti-inflammatory, and antiviral domains. Notable examples include:

  • Anti-Tumor: Soybean-derived gma-miR159a targets the TCF7 transcription factor to reduce breast tumor growth.
  • Anti-Inflammatory: Ginger-derived exosomal RNAs induce IL-22 production, improving intestinal barrier function in colitis models.
  • Antiviral: Honeysuckle-derived miR2911 has shown efficacy in inhibiting Influenza A, SARS-CoV-2, and Enterovirus 71.
Schematic diagram of RNA-mediated immune pathways showing effects on various immune cells.

Delivery Strategies: The Macrophage "Trojan Horse"

Macrophages serve as both targets and delivery vehicles. They naturally scavenge plant-derived extracellular vesicles and can migrate to sites of inflammation or tumors. This "Trojan Horse" mechanism allows for localized drug delivery. Furthermore, plant-derived exosome-like nanovesicles (PENs) are highlighted as superior to synthetic platforms due to their high bioavailability and low immunogenicity.

Challenges and Future Directions

Several "bottlenecks" remain before clinical application:

  1. Standardization: High-purity extraction technologies for plant RNAs are needed.
  2. Dosing: Determining the "minimum effective dose" is difficult due to low detected concentrations in mammalian tissues.
  3. Mapping: A systematic "plant nucleic acid gene library" is required to map plant RNA targets to human genes.
  4. Tracking: Advanced hybridization technologies are necessary to track these molecules' localization within the body.

Summary updated

Abstract

Plant-derived nucleic acids, especially small RNAs have been proved by increasing evidence in the pharmacological activities and disease treatment values in macrophage meditated anti-tumor performance, immune regulating functions and antiviral activities. But the uptake, application and delivery strategies of RNAs as biodrugs are different from the small molecules and recombinant protein drugs. This article summarizes the reported evidence for cross-kingdom regulation by plant derived functional mRNAs and miRNAs. Based on that, their involvement and potentials in macrophage-mediated anti-tumor/inflammatory therapies are mainly discussed, as well as the load prospect of plant RNAs in viruses and natural exosome vehicles, and their delivery to mammalian cells through macrophage were also summarized. This review is to provide evidence and views for the plant derived RNAs as next generation of drugs with application potential in nucleic acid-based bio-therapy.
BibTeX
@inproceedings{liu2023progress,
  author = {Yu-Da Liu and Hao Chen and Yao Zhang and Yan Ge and Hao-Jie Yan and Qi Zhu and Li‐Hua Peng},
  title = {{Progress and challenges of plant-derived nucleic acids as therapeutics in macrophage-mediated RNA therapy}},
  booktitle = {Frontiers in Immunology},
  year = {2023},
  doi = {10.3389/fimmu.2023.1255668},
}
Figure